Accès ouvert déclaré 2026 article

Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study

Léopoldine Lapierre, Lucie Laemmel, Emilie Bérard, Lucie Rigolot, Audrey Bidet, Jules Higué, Anne Banos, Guillaume Béziat, Ramzi Jeddi, Benoît Branco, Claire Calmettes, Noémie Gadaud, Martin Gauthier, Leila Ghenim, Gaëlle Labouré, Clémentine Salvado, Reza Tabrizi, Joséphine Thomazeau, Willy Vaillant, Suzanne Tavitian, Laurent Balardy, Thibaut Leguay, Alban Canali, Émilie Klein, Audrey Sarry, Madeline Mougenot, Eva Baraniecki, Anne-Charlotte de Grande, Pierre Bories, Laëtitia Largeaud, Maël Heiblig, Amine Belhabri, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Martin Carré, Arnaud Pigneux, François Vergez, Sarah Bertoli, Pierre-Yves Dumas, Christian Récher

0Citations signalées, ce qui n’est pas une note de qualité

20Institutions déclarées

1Pays d’affiliation déclarés

Rattachement africain : fr. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result. We analyzed treatment patterns, adverse events, responses and outcomes in 199 patients treated with AZA-VEN in the DATAML registry. The median age was 75.6 years, 48.7% had secondary AML (11% post-MPN); 11.7% had another cancer, and 9% had received AZA for prior myelodysplastic syndrome. Cytogenetic risk was intermediate (55.8%) or adverse (43.7%). The most frequent gene mutations were ASXL1 (33%), TET2 (27%), TP53 (26%), RUNX1 (24%) and SRSF2 (24%). The first cycle was performed on an outpatient basis in 39.4% of patients. The median number of cycles was 4 and 37% received > 6 cycles. Beyond cycle 6, reductions in treatment dose or duration were attributed to VEN in 55% of patients and to AZA for 43%. The complete remission (CR) plus CR with incomplete hematologic recovery (CRi) rate was 58.5%, and day-30 death rate was 3%. Median OS was 8.9 months. mPRS and refined-ELN2024 classifications were significantly associated with response and OS. In CR/CRi patients, G-CSF use was significantly and independently associated with improved OS (median, 10.1 months without vs 20.3 with G-CSF; p=0.001). In an external cohort, G-CSF was also associated with a trend towards improved OS. In real-world clinical practice, patients with more severe characteristics are typically selected for AZA-VEN, which could explain suboptimal outcomes. G-CSF should be prospectively explored in AZA-VEN treated patients. Micro abstract: AZA-VEN has become a standard treatment in older or chemotherapy-ineligible AML patients. We analyzed treatment patterns, adverse events, responses and outcomes in 199 patients treated with AZA-VEN in the DATAML registry. The median age was 75.6 years, 48.7% had secondary AML (11% post-MPN); 11.7% had another cancer, and 9% had received AZA for prior myelodysplastic syndrome. The first cycle was performed on an outpatient basis in 39.4% of patients. The complete remission CR/CRi rate was 58.5%, and day-30 death rate was 3%. Median OS was 8.9 months. mPRS and refined-ELN2024 classifications were significantly associated with response and OS. In CR/CRi patients, G-CSF use was significantly and independently associated with improved OS.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study
Date Crossref: 01/07/2026
Éditeur: Elsevier BV
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Centre Hospitalier Universitaire de Toulouse Service de Gériatrie pays non établi dans la notice
Établissement de santé
Centre Hospitalier Universitaire de Bordeaux pays non établi dans la notice
Établissement de santé
Inserm pays non établi dans la notice
Organisme public
Centre d'Epidémiologie et de Recherche en santé des POPulations de Toulouse pays non établi dans la notice
Structure de recherche
Centre Hospitalier de la Côte Basque pays non établi dans la notice
Établissement de santé
Centre Hospitalier d'Albi pays non établi dans la notice
Établissement de santé
Centre Hospitalier Intercommunal Castres-Mazamet pays non établi dans la notice
Établissement de santé
Centre Hospitalier de Bigorre pays non établi dans la notice
Établissement de santé
Groupe Cahors (France) pays non établi dans la notice
Entreprise
Centre Hospitalier de Dax –Côte d’Argent pays non établi dans la notice
Établissement de santé
Hospices Civils de Lyon pays non établi dans la notice
Établissement de santé
Hôpital Lyon Sud pays non établi dans la notice
Établissement de santé

Service de Gériatrie — Centre Hospitalier Universitaire de Toulouse, Centre Hospitalier Universitaire de Bordeaux et Inserm, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and Treatment

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI